Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

chikungunya virus

- PMLiVE

Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA

There are currently no approved human vaccines for Lyme disease

- PMLiVE

MHRA approves Valneva’s chikungunya vaccine Ixchiq for use in adults

The chikungunya virus has now been identified in over 110 countries in Europe, Asia, Africa and the Americas

- PMLiVE

Valneva shares positive phase 3 results for chikungunya vaccine in adolescents

The company has submitted label extension applications for Ixchiq in this age group

- PMLiVE

Pfizer/Valneva share promising results for Lyme disease vaccine candidate

There are currently no approved human vaccines for the bacterial infection

- PMLiVE

Valneva and LimmaTech Biologics partner to advance Shigella vaccine candidate

There is currently no vaccine approved for Shigella, the second leading cause of fatal diarrhoeal disease globally

- PMLiVE

EC approves Valneva’s single-dose chikungunya vaccine for use in adults

The virus has been identified in over 110 countries in Europe, Asia, Africa and the Americas

- PMLiVE

CHMP recommends Valneva’s chikungunya vaccine for use in adults

If approved, Ixchiq will become the first vaccine available in the EU for the mosquito-borne viral disease

- PMLiVE

Valneva’s single-dose chikungunya vaccine shows promise in adolescents

The mosquito-borne viral disease often causes sudden, large outbreaks with high attack rates

- PMLiVE

Valneva’s chikungunya virus vaccine recommended by US CDC advisory committee

The mosquito-borne viral disease leads to symptomatic disease in 97% of people within a week or less following the mosquito bite

- PMLiVE

Valneva sells FDA priority review voucher for chikungunya vaccine for $103m

The company received a tropical disease PRV in November following the FDA’s approval of Ixchiq for the prevention of disease caused by chikungunya virus

- PMLiVE

Valneva’s chikungunya vaccine approved by FDA for adults at increased exposure risk

The decision makes Ixchiq, which is administered as a single injection, the world's first licensed vaccine against the mosquito-borne disease

- PMLiVE

Bavarian Nordic’s chikungunya vaccine candidate shows promise in late-stage trial

There is currently no approved vaccine or specific treatment for chikungunya virus infections

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links